摘要
探讨肿瘤标志物癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、CA724、细胞角蛋白19片断(CYFRA21-1)和鳞状上皮细胞癌抗原(SCC)联合检测对食管癌诊断、治疗及预后判断的临床价值。用电化学发光免疫分析法(ECLIA)和微粒子酶联免疫测定法(MEIA)检测102例食管癌患者术前和90例术后血清中CEA、CA19-9、CA724、CYFRA21-1和SCC含量。102例食管癌患者血清中5项肿瘤标志物含量均明显高于对照组,随病程增加,阳性率增高。检测90例食管癌患者,术前阳性指标与术后比较,有显著性差异(P<0.01)。五项肿瘤标志物联合检测阳性率为77.5%,高于单项指标检测阳性率,有显著性差异(P<0.01)。血清CEA、CA19-9、CA724、CYFRA21-1和SCC水平动态联合监测可用于食管癌辅助诊断、疗效观察、以及对病期及预后的判断。
To explore the clinical significance of combined detection of CEA, CA19-9, CA724, CYFRA21-1 and SCC levels in the diagnosis, treatment and prognostic judgment of esophageal cancer, the levels of serum CEA, CA19-9, CA724 and CYFRA21-1 in 102 patients with esoph- ageal cancer were measured by electrochemiluminescence immunoassay and the serum SCC level was determined by micro-particle enzyme immunoassay before the operation and the serum levels in 90 of those patients were also measured 10 days after resection. The results showed that the serum levels of five tumor markers in 102 patients with esophageal cancer were significantly higher than that of health controls. The positive rates of these tumor markers were related to the clinical staging of disease. The serum levels of these tumor markers decreased notably after radical operation （P〈0.01）. The positive rate of combined detection of these five markers was 77.5%, it was higher than one of them （P〈0.01）. The dynamic combined detection of CEA, CA19-9, CA724, CYFRA21-1 and SCC could be helpful in the diagnosis, treatment and prognostic judgment of patients with esophageal cancer.
出处
《标记免疫分析与临床》
CAS
2008年第2期65-67,共3页
Labeled Immunoassays and Clinical Medicine
关键词
食管肿瘤
肿瘤标志物
联合检测
Esophageal neoplasm
Tumor marker
Combined detection
